Orthofix (OFIX) Q2 Revenue Rises 2%
Orthofix Medical (NASDAQ:OFIX), a medical device and biologics company specializing in spinal, orthopedic, and bone growth products, reported results for Q2 2025 that modestly beat expectations on both GAAP earnings and non-GAAP revenue. The company announced its earnings for the quarter ended June 30 on August 5, 2025. GAAP revenue totaled $203.1 million for Q2 2025, exceeding the analyst estimate of $196.19 million (non-GAAP). Meanwhile, net loss per share narrowed to $(0.36) on a reported (GAAP) basis, better than the expected $(0.49) (GAAP). Despite ongoing reported losses, the quarter saw improvement in margins (non-GAAP pro forma adjusted gross margin of 72.7%), positive free cash flow of $4.5 million, and continued new product execution. Results marked another quarter of incremental progress against operational and commercial goals.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Orthofix Medical develops, manufactures, and sells medical devices and biologics for spine fusion, complex fracture management, and bone healing. Its product mix includes spinal hardware for spinal fusion, bone growth stimulator devices for bone repair, biologics for surgical procedures, as well as limb lengthening and reconstruction products. The company also offers enabling technologies like navigation systems.
Source Fool.com
